Category

Homepage

COVID-19 Message for the Rett Community

Thursday, June 25, 2020

6.25.20 COVID-19 Community Update As many states begin to re-open, we want to share the following message containing the re-opening status of the U.S. Rett Clinics and guidance from Rettsyndrome.org’s Medical Advisor on returning to therapies and schools. Rett Clinic Re-opening Status The following information summarizes U.S. clinics’ re-opening status for clinical care of Rett … Read More

Chief Science Officer Dr. Dominique Pichard

A Note from Chief Science Officer Dr. Dominique Pichard

Tuesday, November 12, 2019

A Note from Chief Science Officer Dr. Dominique Pichard I am thrilled to be joining Rettsyndrome.org as the Chief Science Officer. Rett syndrome is near and dear to me and my family, as our oldest daughter, Catalina, has Rett syndrome. We received Catalina’s diagnosis when I was still in my medical residency training, and ultimately … Read More

Prichard family

When Molly met Jill: Rett Connection Becomes Fast Friendship

Friday, November 8, 2019

— Becky Sher Molly Prichard jokes that she and best friend Jill Black met “online dating.” And to hear them talk about their fast friendship does sound like a conversation about Internet matchmaking — they mention instant connections, plans to meet in person after finding each other online, and even family members’ concerns that the … Read More

Collage of rett patients

Unwavering in Our Mission

Thursday, October 31, 2019

Rett Syndrome Awareness Month has been incredible. As a community, you rallied like never before – speaking out to share the good, the bad, and the ugly about Rett syndrome to educate the world and move the needle. Your efforts continue to make a difference. Today, more people know about Rett syndrome than ever before … Read More

Acadia pharmaceutials

ACADIA Announces Launch of Phase 3 LAVENDER Study for Trofinetide

Wednesday, October 30, 2019

Dear Rett Community, Today we took a significant step forward with the trofinetide clinical development program initiating the pivotal Phase 3 LAVENDER study. As we have shared before, LAVENDER is a 12-week study that will evaluate the efficacy and safety of trofinetide versus placebo in approximately 180 girls and young women aged 5 to 20 … Read More

Communications Guidelines Pop-up